- ISRAEL21c - http://www.israel21c.org -

NasVax set for $1 million in grants

Posted By Viva Sarah Press On January 31, 2012 @ 8:11 am In | No Comments

Israeli biopharmaceutical firm NasVax has attained provisional approval for nearly $1 million in grant money from the Office of the Chief Scientist.

The grant to NasVax – which develops improved vaccines and immunotherapeutic products – will be divided. Some $460,000 will be used for NasVax’s overseas R&D plan and almost $490,000 will be invested in its R&D in Israel.

NasVax is developing improved vaccines and immunotherapies to treat fatty liver disease and other inflammatory diseases.

In 2011, NasVax announced the success of a Phase 2a clinical trial of a new oral immunotherapy for non-alcoholic steatohepatitis (NASH), an inflammatory disease associated with fatty liver disease and the metabolic syndrome.

NasVax works in four areas: inflammatory and auto-immune diseases; Alzheimer’s disease; pneumococcal vaccines; and enhancing the immunogenicity of vaccines and immunotherapeutics.



Article printed from ISRAEL21c: http://www.israel21c.org

URL to article: http://www.israel21c.org/news/nasvax-set-for-1-million-in-grants/

Copyright © 2012 Israel. All rights reserved.